ANKIB1

Across TCGA pan-cancer cohorts, ANKIB1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKIB1 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ANKIB1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANKIB1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

LSCC, UCEC, and LUAD are the cancer types where ANKIB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.688	0.957	.003	20	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.490	.018	12	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	12	view →
PDAC	DFS	Median	II,III,IV	0.683	0.813	.010	10	view →
CCRCC	OS	Tertile	All	0.920	0.779	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKIB1–LSCC (OS)

Open the LSCC breakdown →